Nanotechnology-Based Targeting of mTOR Signaling in Cancer
Mee-Sup Yoon Department of Molecular Medicine, School of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Republic of KoreaCorrespondence: Mee-Sup Yoon Tel +82-32-899-6067Fax +82-32-899-6039Email msyoon@gachon...
Guardado en:
Autor principal: | Yoon MS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d2a6893fdadb4cce8f8efde3d73d48de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury
por: Wang Xiaoping, et al.
Publicado: (2016) -
Cerebral mTOR signal and pro-inflammatory cytokines in Alzheimer’s disease rats
por: Wang Xu, et al.
Publicado: (2016) -
Dual Targeting by Inhibition of Phosphoinositide-3-Kinase and Mammalian Target of Rapamycin Attenuates the Neuroinflammatory Responses in Murine Hippocampal Cells and Seizures in C57BL/6 Mice
por: Preeti Vyas, et al.
Publicado: (2021) -
Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway
por: Terry Ting-Yu Chiou, et al.
Publicado: (2021) -
Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
por: Peri M, et al.
Publicado: (2020)